Ronald Przygodzki, MD

Dr. Ronald Przygodzki is board certified in anatomic and clinical pathology with sub-specialization in molecular genetic pathology.  He earned his medical degree from the Medical University of Warsaw, as well as residencies in pathology and laboratory medicine at University of Illinois at Chicago and Brown University Rhode Island Hospital, respectively.  Dr.

Molecular Tumor Board: 56 year-old female with Stage IIIC2 endometrial cancer, PD-L1 <1%, MSI-H, TMB-H

Molecular Tumor Board: 48 year-old female with cutaneous melanoma harboring NRAS Q61R mutation

Molecular Tumor Board: 64 year-old female with recurrent breast cancer and PIK3CA mutation

Genetic testing: How iGeniE streamlines result delivery for providers and patients

The landscape of prenatal genetic screening is rapidly evolving, with more conditions, complexity and positive results than ever before. While this information empowers patients, it also creates new challenges for providers. Explaining nuanced genetic concepts is time-consuming, and the concepts can be difficult for patients to grasp in a single appointment. According to a recent scientific study, 88% of patients agree that video explanations make results easier to understand.1

Getting the right care to all for colorectal cancer screenings - How Labcorp worked with a large national plan to improve member health

In an effort to increase testing availability and lower death rates associated with colorectal cancer (CRC), a large national plan partnered with Labcorp to close their colorectal cancer screening gaps in care to more effectively improve member health. They partnered with us because of our successful, nearly 10-year relationship with them and because they’d come to expect excellent results from Labcorp—knowing that everything we do is rooted in science.

Labcorp Declares Quarterly Dividend

BURLINGTON, N.C. , Oct. 12, 2023 /PRNewswire/ --  Labcorp  (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today that its Board of Directors has declared a cash dividend of $0.72 per share of common stock. The dividend will be payable on December 12, 2023

Labcorp Launches New Test to Accelerate Path to Diagnosis of Alzheimer's Disease

Test is available through physicians for use with patients being evaluated for possible Alzheimer's disease or other causes of cognitive impairment Labcorp is the first company to deliver a blood-based Amyloid-Tau-Neurodegeneration (ATN) Profile, which uses a trio of blood biomarkers to detect the